Document Detail

Systemic hematologic status following intraventricular recombinant tissue-type plasminogen activator for intraventricular hemorrhage: the CLEAR IVH Study Group.
MedLine Citation:
PMID:  21940973     Owner:  NLM     Status:  MEDLINE    
BACKGROUND AND PURPOSE: This is the first prospective evaluation of changes in systemic hematologic status following administration of intraventricular recombinant tissue-type plasminogen activator in patients with intraventricular hemorrhage (IVH).
METHODS: Laboratory data from subjects enrolled onto the Clot Lysis: Evaluating Accelerated Resolution of IVH (CLEAR IVH) Trials were analyzed. We analyzed pre- and post- recombinant tissue-type plasminogen activator dosing coagulation parameters. Longer-term changes in hematologic status were studied in subjects who received the study agent after blood clot in the third/fourth ventricles had resolved radiologically.
RESULTS: Plasma fibrinogen increased significantly in both treatment groups. Dosing did not have a significant impact on any systemic coagulation parameters in either treatment group.
CONCLUSIONS: Intraventricular recombinant tissue-type plasminogen activator is unlikely to impact systemic coagulation or to compound the effects of systemic anticoagulation for deep venous thrombosis prophylaxis.
CLINICAL TRIAL REGISTRATION: URL: Unique identifier: NCT00650858.
Daniel B Herrick; Wendy C Ziai; Carol B Thompson; Karen Lane; Nichol A McBee; Daniel F Hanley
Related Documents :
11464043 - Extracorporeal shock wave lithotripsy in children. efficacy, complications and long-ter...
15891573 - Transient cochlear ischemia and its effects on the stria vascularis.
8709173 - Patients' needs and their coping strategies transition to cardiac surgery.
Publication Detail:
Type:  Controlled Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.     Date:  2011-09-22
Journal Detail:
Title:  Stroke; a journal of cerebral circulation     Volume:  42     ISSN:  1524-4628     ISO Abbreviation:  Stroke     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2011-11-29     Completed Date:  2012-08-13     Revised Date:  2013-06-27    
Medline Journal Info:
Nlm Unique ID:  0235266     Medline TA:  Stroke     Country:  United States    
Other Details:
Languages:  eng     Pagination:  3631-3     Citation Subset:  IM    
Department of Neurology, Johns Hopkins University, School of Medicine, BA, 1550 Orleans Street, CRB-II 3M50, Baltimore, MD 21231, USA.
Data Bank Information
Bank Name/Acc. No.:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Coagulation / drug effects*
Cerebral Hemorrhage / drug therapy*,  physiopathology
Cerebral Ventricles / drug effects,  physiopathology
Dose-Response Relationship, Drug
Fibrinogen / metabolism
Injections, Intraventricular
Middle Aged
Platelet Count
Retrospective Studies
Thrombolytic Therapy*
Tissue Plasminogen Activator / administration & dosage*,  therapeutic use
Grant Support
FD-R 002018/FD/FDA HHS; FD-R-001693/FD/FDA HHS; U01 NS062851/NS/NINDS NIH HHS; U01 NS062851-01A1/NS/NINDS NIH HHS
Reg. No./Substance:
9001-32-5/Fibrinogen; EC Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Blood-brain barrier breakdown in acute and chronic cerebrovascular disease.
Next Document:  Intracranial Stenting of Subacute Symptomatic Atherosclerotic Occlusion Versus Stenosis.